Market Overview:
The global bone cancer diagnosis and therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of bone cancer, increasing awareness about bone cancer, and technological advancements in the field of diagnostics and therapeutics. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, radiation therapies are expected to account for the largest share in this market during the forecast period. This can be attributed to their ability to provide localized treatment without causing any damage to healthy tissues surrounding tumor cells.
Product Definition:
Bone cancer is a type of cancer that begins in the bones. Bone cancers can be primary, which start in the bone cells, or secondary, which start somewhere else in the body and spread (metastasize) to the bones. Bone cancers are rare; they account for only about 1% of all cancers.
Radiation therapies:
Radiation therapies, it's usage and growth factor in Bone Cancer Diagnosis.
The global radiation therapy, it's usage and growth factor in bone cancer diagnosis & therapeutics market is expected to witness significant growth over the forecast period. Increasing prevalence of bone cancer coupled with rising awareness about available treatment options are some factors attributing to the estimated increase in demand for radiation therapy.
Chemotherapy:
Chemotherapy is the use of drugs or chemical agents to treat cancer. The most common types of cancers that are treated with chemotherapy include breast cancer, lung cancer, prostate cancer, and bone & brain tumors. Chemotherapy can be used in combination with radiation therapy or surgery (inoperative treatment), or it can be used alone as an active form of treatment (watchful waiting).
Application Insights:
The other application segment dominated the market in 2017 and is expected to continue its dominance over the forecast period. Other applications include surgical treatment, radiation therapy, chemotherapy and cryosurgery. The growing usage of targeted therapies for treating bone cancer is one of the key factors driving this segment. For instance, bevacizumab (Avastin) is used as a first-line therapy for metastatic breast cancer that has spread to bones or organs in patients who have received chemotherapy or radiation therapy.
In addition, new product approvals are also expected to fuel growth during this period such as palifosfamide (PAL-AFOSFAMIDE), an autophosphorylation inhibitor which was approved by FDA under priority review program on June 29th 2018 for use with fluoropyrimidine and 5-fluorouracil based chemotherapeutic drugs for treating advanced soft tissue tumors including bone metastasis from breast carcinoma.
Regional Analysis:
North America dominated the global bone cancer diagnosis and therapeutics market in 2017. This is due to the presence of key players, availability of advanced technologies, high patient awareness levels coupled with a higher per capita healthcare expenditure in this region as compared to other regions. Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing geriatric population base and rising incidences of osteosarcoma & malignant peripheral nerve sheath tumor (MPNST) especially in developing countries such as India & China. In addition, an increase in disposable income will also contribute towards regional growth over the forecast period.
The bone cancer diagnostics industry has been segmented into North America, Europe, Asia Pacific (APAC), Latin America and MEA on account of different regulatory policies enforced by each region governing diagnostic tests or therapies used for disease management purposes respectively.
Growth Factors:
- Increasing incidence of bone cancer
- Growing demand for better diagnostic and therapeutic options
- Rising awareness about bone cancer and its treatment options
- Technological advancements in diagnosis and therapeutics for bone cancer
- Availability of government funding for research on bone cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Bone Cancer Diagnosis and Therapeutics Market Research Report
By Type
Radiation therapies, Chemotherapy, Cryosurgery, Surgical treatment, Targeted therapy
By Application
Multispecialty hospitals, Cancer research centers, Other
By Companies
Ablynx, Allergan, AVEO Pharmaceuticals, Amgen, Novartis, Bayer, Pfizer, Celldex Therapeutics, Debiopharm, Eli Lilly, Roche, Galapagos, Infinity Pharmaceuticals, Medivir, Merrion Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Bone Cancer Diagnosis and Therapeutics Market Report Segments:
The global Bone Cancer Diagnosis and Therapeutics market is segmented on the basis of:
Types
Radiation therapies, Chemotherapy, Cryosurgery, Surgical treatment, Targeted therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multispecialty hospitals, Cancer research centers, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ablynx
- Allergan
- AVEO Pharmaceuticals
- Amgen
- Novartis
- Bayer
- Pfizer
- Celldex Therapeutics
- Debiopharm
- Eli Lilly
- Roche
- Galapagos
- Infinity Pharmaceuticals
- Medivir
- Merrion Pharmaceuticals
Highlights of The Bone Cancer Diagnosis and Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radiation therapies
- Chemotherapy
- Cryosurgery
- Surgical treatment
- Targeted therapy
- By Application:
- Multispecialty hospitals
- Cancer research centers
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bone Cancer Diagnosis and Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bone cancer is a type of cancer that starts in the bones. Bone cancer can be treated with surgery, radiation therapy, and chemotherapy.
Some of the major companies in the bone cancer diagnosis and therapeutics market are Ablynx, Allergan, AVEO Pharmaceuticals, Amgen, Novartis, Bayer, Pfizer, Celldex Therapeutics, Debiopharm, Eli Lilly, Roche, Galapagos, Infinity Pharmaceuticals, Medivir, Merrion Pharmaceuticals.
The bone cancer diagnosis and therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bone Cancer Diagnosis and Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bone Cancer Diagnosis and Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bone Cancer Diagnosis and Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bone Cancer Diagnosis and Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bone Cancer Diagnosis and Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Bone Cancer Diagnosis and Therapeutics Market Size and Y-o-Y Growth
4.5.2 Bone Cancer Diagnosis and Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Radiation therapies
5.2.2 Chemotherapy
5.2.3 Cryosurgery
5.2.4 Surgical treatment
5.2.5 Targeted therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Multispecialty hospitals
6.2.2 Cancer research centers
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bone Cancer Diagnosis and Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bone Cancer Diagnosis and Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Radiation therapies
9.6.2 Chemotherapy
9.6.3 Cryosurgery
9.6.4 Surgical treatment
9.6.5 Targeted therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Multispecialty hospitals
9.10.2 Cancer research centers
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Radiation therapies
10.6.2 Chemotherapy
10.6.3 Cryosurgery
10.6.4 Surgical treatment
10.6.5 Targeted therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Multispecialty hospitals
10.10.2 Cancer research centers
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Radiation therapies
11.6.2 Chemotherapy
11.6.3 Cryosurgery
11.6.4 Surgical treatment
11.6.5 Targeted therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Multispecialty hospitals
11.10.2 Cancer research centers
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Radiation therapies
12.6.2 Chemotherapy
12.6.3 Cryosurgery
12.6.4 Surgical treatment
12.6.5 Targeted therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Multispecialty hospitals
12.10.2 Cancer research centers
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Radiation therapies
13.6.2 Chemotherapy
13.6.3 Cryosurgery
13.6.4 Surgical treatment
13.6.5 Targeted therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Multispecialty hospitals
13.10.2 Cancer research centers
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bone Cancer Diagnosis and Therapeutics Market: Competitive Dashboard
14.2 Global Bone Cancer Diagnosis and Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ablynx
14.3.2 Allergan
14.3.3 AVEO Pharmaceuticals
14.3.4 Amgen
14.3.5 Novartis
14.3.6 Bayer
14.3.7 Pfizer
14.3.8 Celldex Therapeutics
14.3.9 Debiopharm
14.3.10 Eli Lilly
14.3.11 Roche
14.3.12 Galapagos
14.3.13 Infinity Pharmaceuticals
14.3.14 Medivir
14.3.15 Merrion Pharmaceuticals
